Research programme: cancer therapeutics - FORMA Therapeutics/Novartis
Latest Information Update: 22 May 2012
At a glance
- Originator FORMA Therapeutics
- Developer FORMA Therapeutics; Novartis
- Class Small molecules
- Mechanism of Action Protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer